“We will develop organoid-based new medicines and realize customized precision medicine.” Hong Jun-ho, vice president at the Planning and Coordination Head Office of the Interpark’s Bio-Convergence Center, said so in a recent interview with Korea Biomedical Review. Hong Jun-ho, vice president at the Planning and Coordination Head Office of […]
View Original Source at Interpark embarks on organoid business